This pathway controls autonomic and endocrine function (Dedic et al., 2018; Deussing and Chen, 2018; Godoy et al., 2018), and CRFR2-selective agonists modulate metabolic activity in obesity models (Jamieson et al., 2011; Chen et al., 2013; Paruthiyil et al., 2018) and immune response in models of sepsis (Gonzalez-Rey et al., 2006a), Crohn’s disease (Gonzalez-Rey et al., 2006b), rheumatoid arthritis (Gonzalez-Rey et al., 2007) and cancer (Argilés et al., 2008), suggesting that CRFR2 plays a fundamental role. Here, CRHR2 is linked to obesity disorder.